Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1181181, R
Drug: BI 1181181
Drug: BI 1181181, T2
Drug: Placebo to BI 1181181
Drug: BI 1181181, T1

First Posted Date: 2014-01-24

Last Posted Date: 2014-10-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT02044406

Locations: 🇩🇪
1344.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate

First Posted Date: 2014-01-24

Last Posted Date: 2015-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 54

Registration Number: NCT02044367

Locations: 🇩🇪
1160.194.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Interaction of BI 691751 With Itraconazole

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 691751
Drug: itraconazole

First Posted Date: 2014-01-24

Last Posted Date: 2015-12-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02044393

Locations: 🇩🇪
1334.10.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2014-01-23

Last Posted Date: 2015-07-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25586

Registration Number: NCT02043808

Locations: 🇺🇸
1160.183.01 Boehringer Ingelheim Investigational Site, Lexington, Massachusetts, United States

Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to BI 1026706
Drug: BI 1026706
Drug: Pregabalin
Drug: Celecoxib

First Posted Date: 2014-01-15

Last Posted Date: 2019-07-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02037165

Locations: 🇩🇪
1320.3.1 Boehringer Ingelheim Investigational Site, Dornach, Germany

Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lasolvan tablet
Drug: Lasolvan effervescent tablet
Drug: Lasolvan prolonged-released capsules
Drug: Lasolvan prolonged-release hard capsule

First Posted Date: 2014-01-15

Last Posted Date: 2015-05-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02036775

Locations: 🇷🇺
18.510.2 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation

Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: olodaterol
Drug: tiotropium

First Posted Date: 2014-01-08

Last Posted Date: 2015-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT02030535

Locations: 🇩🇪
1237.7.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪
1237.7.49007 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
🇩🇪
1237.7.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany

and more 3 locations

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin 2.5 mg
Drug: Empagliflozin/Metformin FDC
Drug: Empagliflozin 10 mg
Drug: Metformin 500 mg

First Posted Date: 2014-01-07

Last Posted Date: 2015-07-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02028767

Locations: 🇨🇦
1276.24.001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to dose
Drug: Placebo to Idarucizumab
Drug: Idarucizumab
Drug: dabigatran

First Posted Date: 2014-01-07

Last Posted Date: 2016-02-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT02028780

Locations: 🇯🇵
1321.5.00001 Boehringer Ingelheim Investigational Site, Sumida-ku, Tokyo, Japan

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2013-12-27

Last Posted Date: 2017-01-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 220

Registration Number: NCT02022020

Locations: 🇨🇦
Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy